



## Novel Therapeutic Strategies for Lung Cancer in the Era of Personalized Treatment

Guest Editors:

**Dr. Konstantinos Porpodis**

Department of Pulmonary  
Medicine, General Hospital of  
Thessaloniki 'Georgios  
Papanikolaou', Aristotle  
University of Thessaloniki, 57010  
Exohi Thessaloniki, Greece

**Dr. Kelly Domvri**

1. Department of Pathology,  
General Hospital of Thessaloniki  
'Georgios Papanikolaou',  
Thessaloniki, Greece  
2. Laboratory of Histology-  
Embryology, Medical School,  
Aristotle University of  
Thessaloniki, Thessaloniki,  
Greece

Deadline for manuscript  
submissions:

**closed (10 September 2022)**

### Message from the Guest Editors

Dear Colleagues,

Lung cancer still remains as the world's leading cause of cancer death. Clinical development of immune checkpoint inhibitors (ICIs) has dramatically changed the prognosis of patients with non-small cell lung cancer. Of note, for the first time in 30 years, immunotherapy has also shown a survival benefit in patients with small cell lung cancer. Despite these advantages, the identification of reliable biomarkers is critical in efforts to further identify a subset of patients that may benefit from immunotherapy. Moreover, a combination of ICIs with other treatments is now under investigation to extend their efficacy in lung cancer patients.

Thus, the aim of this Special Issue is to highlight recent studies on therapeutic strategies and biomarker evaluation in lung cancer.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)